Table 1. Baseline clinical and angiographic characteristics of the study population.
| Variables | NSTEMI SYNTAX score ≥ 32 (n = 35) | NSTEMI SYNTAX score < 32 (n = 45) | NCA (n = 29) | p value* | p value# | p value† | p value‡ |
| Age,years | 62.94 ± 9.49 | 62.29 ± 8.25 | 58.90 ± 10.64 | 0.187 | |||
| BMI, kg/m2 | 30.03 ± 5.67 | 30.09 ± 4.99 | 29.90 ± 6.13 | 0.989 | |||
| Waist circumference, cm | 90.28 ± 7.21 | 88.02 ± 6.67 | 87.45 ± 5.42 | 0.168 | |||
| Systolic blood pressure, mmHg | 136.48 ± 7.35 | 135.66 ± 10.87 | 136.79 ± 5.75 | 0.843 | |||
| Diastolic blood pressure, mmHg | 84.65 ± 6.36 | 84.60 ± 9.53 | 85.00 ± 4.51 | 0.973 | |||
| Female, n (%) | 12 (34.3) | 11 (22.4) | 8 (27.6) | 0.622 | |||
| Hyperlipidemia, n (%) | 17 (48.6) | 21 (46.7) | 6 (20.7) | 0.041 | |||
| Diabetes mellitus, n (%) | 13 (37.1) | 10 (22.2) | 7 (24.1) | 0.298 | |||
| Smoking, n (%) | 17 (48.6) | 28 (62.2) | 8 (27.6) | 0.014 | < 0.001 | < 0.001 | < 0.001 |
| Previous MI, n (%) | 5 (14.3) | 11 (24.4) | 0 (0.0) | 0.015 | < 0.001 | ||
| Multi-vessel disease, n (%) | 32 (91.4) | 30 (66.7) | 0 (0.0) | < 0.001 | < 0.001 | ||
| Chronic total occlusion, n (%) | 13 (37.1) | 7 (15.6) | 0 (0.0) | < 0.001 | < 0.001 | ||
| Stent implantation, n (%) | 15 (42.8) | 29 (64.4) | 0 (0.0) | < 0.001 | < 0.001 | ||
| Decision for CABG, n (%) | 15 (42.8) | 5 (11.1) | 0 (0.0) | < 0.001 | < 0.001 | < 0.001 | < 0.001 |
| Collateral vessel, n (%) | 10 (28.6) | 4 (8.9) | 0 (0.0) | 0.018 | |||
| SYNTAX score | 37.77 ± 3.66 | 17.88 ± 7.13 | 0 ± 0 | < 0.001 | |||
| LVEF, % | 53.92 ± 10.86 | 51.82 ± 8.89 | 58.04 ± 6.85 | 0.035 | 0.619 | 0.24 | 0.026 |
| Drug usage, n (%) | |||||||
| β blockers | 8 (22.9) | 7 (15.6) | 2 (6.9) | 0.193 | |||
| ACEi/ARB | 7 (20.0) | 14 (31.1) | 5 (17.2) | 0.318 | |||
| Calcium channel blocker | 6 (17.1) | 7 (15.6) | 5 (17.2) | 0.975 | |||
| Spironolactone/diuretics | 7 (20.0) | 7 (15.6) | 4 (13.8) | 0.784 | |||
| Statins | 13 (37.1) | 10 (22.2) | 7 (24.1) | 0.298 | |||
| Antidepressant | 5 (14.3) | 7 (15.6) | 5 (17.2) | 0.949 | |||
| ASA | 7 (20.0) | 7 (15.6) | 1 (3.4) | 0.145 | |||
| Klopidogrel/ticagrelor/prasugrel | 2 (5.7) | 2 (4.4) | 0 (0.0) | 0.273 | |||
| Warfarin/NOAC | 2 (5.7) | 2 (4.4) | 0 (0.0) | 0.273 | |||
| Insulin | 3 (8.6) | 2 (4.4) | 0 (0.0) | 0.154 | |||
| Oral antidiabetic | 13 (37.1) | 10 (22.2) | 7 (24.1) | 0.298 |
Data are given as mean ± SD, n (%) or median (lower-upper limit).
ACEi, angiotensin converting enzyme inhibitors; ARB, angiotensin II receptor blockers; ASA, acetylsalicylic acid; BMI, body mass index; CABG, coronary artery bypass grafting; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NCA, normal coronary artery; NOAC, novel oral anticoagulants; NSTEMI, non ST-segment elevation myocardial infarction.
§ Parameters without normally distributed (One-Way ANOVA test was used to show the differences between the three groups in continuous numeric parameters with normal distribution. Tukey's test was used for the post-hoc analysis. Kruskal-Wallis test was used for the differences between the three groups in parameters without normally distributed, if there was statistical significance the Mann-Whitney U test was used for nonpaired groups. Differences between three groups for the categorical variables were analyzed using the chi-square test.)
* p value between all groups. # p value between NSTEMI SYNTAX score ≥ 32 and NSTEMI SYNTAX score < 32 groups. † p value between NSTEMI SYNTAX score ≥ 32 and NCA groups. ‡ p value between NSTEMI SYNTAX score < 32 groups and NCA groups groups.